Drug Approval | July 26, 2024
USFDA inspects Gland Pharma’s Dundigal facility
The inspection was concluded with two 483 observations
The inspection was concluded with two 483 observations
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Reported profit after tax declined 19% year-on-year to Rs 76 crores
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
Subscribe To Our Newsletter & Stay Updated
